Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alembic Pharma gets...

    Alembic Pharma gets USFDA nod for hypertension tablets

    Written by supriya kashyap kashyap Published On 2016-11-20T11:24:34+05:30  |  Updated On 20 Nov 2016 11:24 AM IST

    New Delhi : Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for its Telmisartan and Amlodipine tablets used for treatment of hypertension.


    The company has received approval from the US Food and Drug Administration (USFDA) for Telmisartan and Amlodipine tablets in the strengths of of 40mg/5 mg, 40mg/10 mg, 80mg/5 mg and 80mg/10 mg, Alembic Pharma said in a BSE filing.


    The company's product is generic version of Boehringer Ingelheim Pharmaceuticals Inc's Twynsta tablets in the same strengths, it added.


    The company now has a total of 50 abbreviated new drug application (ANDA) approvals (44 final approvals and six tentative approvals) from the USFDA, Alembic Pharma said.


    Shares of Alembic Pharmaceuticals today closed at Rs 602.25 per scrip on BSE, down 1.20 per cent from its previous close.

    Abbreviated New Drug ApplicationAlembicANDABoehringer Ingelheimhypertensionhypertension tabletsTelmisartan and Amlodipine tabletsUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok